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lines of Polish Agency for Health Technology Assessment. RESULTS: As a result of
a systematic search of publications, one single-blind, randomized clinical trial
(Flowers 2008), fulfilling the predefined inclusion criteria, was found. The trial di-
rectly compared the clinical effectiveness of extracorporeal photopheresis com-
bined with conventional therapy vs conventional therapy alone in the treatment of
cutaneous cGvHD that could not be controlled by steroids. Moreover, there were
identified 45 non-randomised, single-arm clinical trials which assessed the clinical
effectiveness of ECP in analysed indications. Based on identified clinical trials it
could be concluded that there is clinically relevant response to ECP treatment
among patients with acute or chronic GvHD. The highest improvement was ob-
served in skin, liver and gut among patients with aGvHD and in skin but also in
mucosa, liver and lungs involvement among patients with cGvHD. Moreover, it was
showed that ECP treatment is connected with reduction in the use of immunosup-
pressant (mainly steroids) in both groups of patients: with acute or chronic steroid-
refractory or steroid-dependant GvHD. The reduction in steroid dose allows to
reduces the risk of life-threatening bacterial, viral and fungal infections. ECP is very
well tolerated procedure. Infrequent adverse events are usually mild and seldom
led to discontinuation of the treatment. CONCLUSIONS: Results obtained from
clinical trials included in the systematic review showed that there exists clinical
benefit associated with the use of ECP in the treatment of pediatric and adult
patients with steroid-refractory, steroid-dependant acute or chronic GvHD.
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OBJECTIVES: To evaluate real-world effectiveness and device complication out-
comes of the LAP-BAND AP® System adjustable gastric band (LAGB) one year after
surgical implantation. METHODS: HERO study is a 5-year registry of 1,106 severely
or morbidly obese subjects from 29 centers in North America, Europe, and Australia
implanted with LAGB. In the current analyses, the mean change in body mass
index (BMI) and percentage excess weight loss (%EWL) at 1 year are determined.
Rates of device complication events as well surgical revisions and explants at 1 year
are also reported. RESULTS: The mean age of subjects was 43.1 years and females
constituted 79.3%. The mean(SD) weight and BMI at baseline was 126.2(24.1) kg and
45.1(6.9) kg/m2 respectively. At 1 year, the mean (SD) BMI decreased by 7.7(4.4)
kg/m2 and the average(SD) %EWL was 39.8(22.3)%. One (0.1%) death occurred from
liver cancer and was deemed not related to the device. Of 47 subjects with 53 device
complication events at 1 year, 18 (1.6%) experienced an event at 3-months, 9 (0.8%)
at 6-months, and 20 (1.8%) at 1-year. Subjects who reported device complications
were port displacement (1.8%), pouch dilatation (0.8%), band erosion (0.5%), device-
related infection (0.5%), band slippage (0.4%), port leak (0.1%), and both band slip-
page and pouch dilatation (0.3%). Eighteen (1.6%) subjects had explants and 3 (0.3%)
had the LAGB surgically revised and replaced. The indications for explants in-
cluded band erosion, band slippage, band intolerance, esophageal dilatation,
pouch dilatation, device-related infection, abdominal pain, dysphagia, and small
bowel obstruction. Minor device related revisions included access port revision
23(2.1%) and reposition of LAGB 4(0.4%). CONCLUSIONS: LAGB was associated with
significant weight loss, with less than 2% of subjects undergoing explantation of
the device within year 1 of this 5-year on-going study. Many reported device com-
plications were considered to be non-serious and could be corrected in an outpa-
tient setting.
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OBJECTIVES:After decades of warfarin as the dominant strategy for stroke preven-
tion in atrial fibrillation (SPAF), new treatments are available. These include new
pharmaceuticals like dabigatran etexilate and a device based approach, left atrial
appendage closure (LAAC). Studies have compared the economics of pharmaceu-
tical treatments, but the cost implications of the device-based approach with high
initial procedural costs compared to these new drugs, with high annual costs for
life, have not been demonstrated. This analysis compares overall costs of SPAF
with LAAC to dabigatran 110mg twice daily.METHODS:An Excel-based cost impact
model was developed using data from PROTECT-AF (Holmes 2009) and RE-LY clin-
ical trial (Connelly 2009), both of which evaluated patients with a CHADS2 score1.
These studies reported similar rates of adverse events, with the exception of bleed-
ing events which were more frequent in dabigatran patients. The model captures
all costs associated with treatment, discontinuation of care and complications.
Costs were based on the German system, using published DRGs and tariffs associ-
ated with procedures, drugs, and disability care. RESULTS: First year average per
patient cost of LAAC was €11,076 compared to €3,251 for dabigatran. However, the
overall cost of care at 5 years for LAAC (€13,547) was less than dabigatran (€13,675)
due to higher annual drug and complication costs in the dabigatran arm.
CONCLUSIONS: Although LAAC was higher cost than dabigatran in the first year,
the total cost of care for dabigatran increased substantially each year, compared to
only modest annual costs for LAAC past the first year. The full burden of costs
associated with dabigatran is higher than with LAAC after five years and continues
to accrue due to high regular annual costs. This is an important consideration for
budget holders in evaluating lifetime treatment when many AF patients are now
living into their eighties and beyond.
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OBJECTIVES: Major practice changes require both clinical and economic rationale,
especially where a novel device replaces an established pharmaceutical therapy.
Recent studies have reported the clinical benefits of percutaneous left atrial ap-
pendage closure (LAAC) for stroke prevention in atrial fibrillation (SPAF) as com-
pared to standard warfarin anticoagulation, but the cost implications of the device-
based approach have not yet been demonstrated. This analysis highlights the
ongoing costs of complications associated with a long standing pharmaceutical
therapy compared to a device-based approach. METHODS: An Excel-based cost
impact model was developed using data from the PROTECT-AF clinical trial which
randomized 707 AF patients to either LAAC or warfarin (Holmes 2009). The model
captured the costs of complications in AF, including strokes, systemic embolism,
major extracranial bleeding and complications associated with the LAAC proce-
dure. Costs for stroke included only the acute, direct costs and did not capture the
long-term societal costs associated with disability. Germany, which recently rec-
ognized the LAAC procedure with a unique DRG code, was the basis for costs, using
published DRGs and tariffs associated with procedures, drugs, and care. RESULTS:
The high rate of adverse events in the warfarin arm generated €6,414 in medical
costs for complications per patient at 5 years, compared to €3,276 for LAAC. These
included mean costs of €3,239 for stroke and systemic embolism and €970 for major
bleeding in the warfarin arm, compared to €1,551 and €484 respectively for LAAC.
The mean annual cost of complications for warfarin was roughly twice that of
LAAC, (€1,283 versus €655). CONCLUSIONS: The complication cost differential
highlights the need for decision makers to consider the totality of long-term costs
and clinical implications of lifetime treatment strategies for SPAF.
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OBJECTIVES: To model the financial impact for the health care institution of spec-
imen rejection due to preanalytical errors in the laboratory testing phase, using
institution specific data. METHODS: Critical data such as number of beds; overall
budget; number of patients of different types seen each year; and number of sam-
ple rejections, as well as qualitative data, eg. probable impact of sample rejection
were collected by interviewing institution staff from multiple country institutions
(N10). The data were then entered into a model to calculate the possible financial
impact of laboratory sample rejections. The model separates patients into different
groups according to the likely effects of having a sample rejected, the probability
that the rejection would have a low, medium or high impact and the consequences
on institution time and resources. The overall consequence, or opportunity cost,
was expressed as patient treatment time and financial cost. RESULTS: The size of
the institutions ranged from 326 to 1,200 beds, with total operating costs varying
between €41 million and €1.1 billion. The number of blood tests per month was
between 37,000 and 458,000 and of these between 0.09% and 2% were rejected
(mean 0.93%). The total cost of specimen rejection ranged from €22k to €5.9 million
per annum (mean €1.9 million), equating to a percentage of total operating costs
from 0.1% to 1.2% (mean 0.4%). The estimated cost per patient for a sample rejec-
tion was from €29 to €349 (mean €171). CONCLUSIONS: A customisable model
allows institutions to estimate, using local data and assumptions, the effect of
sample rejection on patient treatment and cost. Results can be compared to those
from other institutions to benchmark performance and assumptions. The results
demonstrated that a reduction in the number of rejected samples due to preana-
lytical errors could lead to significant cost savings for most institutions.
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OBJECTIVES: Needlestick injuries (NSIs) represent a significant clinical and eco-
nomic burden to health care systems and society. The EU Directive on the preven-
tion of sharps injuries recommends adherence to a range of safety measures, of
which providing safety-engineered devices (SEDs) forms a key part. An economic
model was constructed to investigate the potential hospital budget savings asso-
ciated with the use of SEDs rather than conventional (i.e. non-safety-engineered)
devices when conducting procedures with sharp devices. METHODS: An inci-
dence-based, deterministic budget impact model with a five-year time horizon was
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developed from the perspective of a Belgian hospital. Costs are discounted at 3%, in
line with Belgian guidelines for pharmacoeconomic evaluation. The model takes
into account device acquisition costs and other direct and indirect costs associated
with NSIs occurring from infusion, injection, blood collection and insulin admin-
istration for diabetes care. Model input data were derived from the Institut National
d’Assurance Maladie-Invalidité (INAMI), published studies, clinical guidelines, and
market research. RESULTS: For a 420 bed hospital, an estimated 384,720 sharps
procedures occur annually. Over five years, the total cost of conducting these pro-
cedures using conventional devices was estimated to be €580,700, of which
€326,700 or 56% was spent managing 310 NSIs. If all procedures were instead con-
ducted using SEDs, the model estimates that the number of NSIs would be reduced
to 75. Total costs with SEDs are estimated to be €528,500, representing an overall
cost saving of €52,200 or 9%. Greater acquisition costs for SEDs are offset by a
decline in NSI management costs. CONCLUSIONS: Costs associated with NSIs are a
significant avoidable cost of conducting sharps procedures. SEDs may reduce the
economic burden of managing NSIs, which may partially or completely offset any
increase in device acquisition costs.
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OBJECTIVES: Coronary angiography is the current gold standard in diagnosing
coronary lesions. However, coronary angiography does not definitively determine
whether a lesion is ischemic or not. Compared to angiography alone, Fractional
Flow Reserve (FFR) has demonstrated clinical superiority in diagnosing cardiac
lesion functional severity, while concurrently providing cost savings. The goal of
this model is to demonstrate the hospital budgetary implications of utilizing FFR to
guide clinical decision making in PCIs compared to angiography alone. METHODS:
A customizable Excel®-based hospital budget impact model was developed for a
hypothetical cohort of 500 patients with multivessel coronary disease. Cost com-
ponents included procedural, device, hospital stay and cardiovascular complica-
tion costs during the one-year period after PCI. A decision tree model was utilized
to convert the expected probabilities of cardiovascular complications into expected
costs. Probabilities and costs were derived from The Fractional Flow Reserve versus
Angiography for Multivessel Evaluation (FAME) clinical trial data. Costs were con-
verted to 2011 US dollars. Sensitivity analysis was carried out over reported ranges
of values of model inputs. RESULTS: Using Fractional Flow Reserve in 20% of the
multivessel cases resulted in estimated cost savings of $297,247 per year compared
to using angiography alone in all of the multivessel cases. Fractional Flow Reserve
usage resulted in reduced costs of the procedure, hospital stay and complications.
Potential cost savings were most sensitive to variations in the cost of hospitaliza-
tion and the probabilities of cardiovascular complications. CONCLUSIONS: Analy-
sis shows that compared to angiography alone, FFR-guided coronary intervention
for patients with multivessel disease both (1) reduces rates of adverse events and
(2) reduces total costs including procedural, hospital and complication costs. As
such, FFR provides hospitals a cost saving technology with superior clinical out-
comes as compared to angiography alone
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OBJECTIVES: Care for cardiovascular diseases is an important issue for health care
systems. Coronary artery bypass grafting surgery (CABG) is utilized to treat coro-
nary artery disease. Intensive care stay (ICS) and acute stroke (AS) are important
drivers of post-operative costs. In Turkey, ICS and AS receive add-on payments to
the packaged payment for CABG from the Social Security Agency (SGK). Effective
use of regional cerebral oxygen saturation monitoring (rSO2) during CABG reduces
intensive care stay (ICS) from 1,87 to 1,25 days and acute stroke (AS) incidence from
2,21% to 0,61%. We modelled the potential impact of SGK add-on payment for rSO2
on SGK add-on payments for ICS and AS after CABG.METHODS: Turkish volume of
CABG was estimated as 47.973 procedures for 2012 (Covidien ICD-10 study of Tur-
key), increasing at 7,2% per year (National Cardiology Policy Report). SGK was as-
sumed to cover 75% of procedures. ICS cost was taken from SGK. AS cost was taken
from published data. Add-on payment for rSO2 was taken as 400TL per patient (cost
of Covidien INVOS™ disposable sensor). Utilization of rSO2 in CABG with add-on
payment was estimated as 15% in 2013, 30% in 2014, and 50% in 2015. Discount rate
was 5%. RESULTS: Under current care paradigms, estimated SGK cost for ICS and
AS following CABG will be 82,9, 84,5 and 86,0 million TL in 2013, 2014 and 2015, respec-
tively. However, if add-on payment facilitates utilization and benefits of rSO2 in CABG,
potential SGK cost for ICS and AS following CABG would decrease to 78,5, 75,3 and 70,6
million TL in those years. CONCLUSIONS: The cost of ICS and AS after CABG is
substantial in Turkey. Add-on payment for rSO2 during CABG may decrease cumu-
lative ICS and AS costs by approximately 29 million TL between 2013 and 2015.
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OBJECTIVES: Recent literature suggests complication rates associated with current
Vascular Closure Devices (VCDs) are comparable or reduced when compared to
manual compression. However, well-documented differences exist among VCDs
regarding the type and frequency of complications. A recent global budget impact
model based on a naïve indirect treatment comparison (ITC) estimated the cost-
savings associated with use of the VCD EXOSEAL™ vs. Angioseal™, Starclose™,
Perclose™ and Mynx™ from the US hospital perspective. Based on this ITC, the
analysis was adapted to Italy and Spain from the National Health System (NHS)
perspective over a 1 year time horizon. METHODS: The ITC was used to calculate
the incidence of reinterventions (i.e. amputation (AM), vascular surgery (VS), en-
dovascular procedure (EP), transfusion (TR) and ultrasound guided interventions
(UGI)) following complications associated with each VCD. The annual number of
VCDs used and costs of reinterventions were obtained from local databases. The
means and 95% confidence intervals (95%-CI) for the budget impact were estimated
using bootstrap methods (1.000 simulations) assuming 100% use of ExosealTM vs.
100% use of another VCD, and 100% use of Exoseal vs. 2010 VCD market-share for
percutaneous coronary interventions (PCI) procedures. Device acquisition costs
were assumed identical. RESULTS: Savings per procedure with EXOSEAL™ (Italy/
Spain) would be approximately of (22,8€/11,9€) vs. Angioseal™, (15,5€/13,5€) vs.
Starclose™, (83,1€/72,6€) vs. Perclose™ and (11,2€/16,4€) vs. Mynx™. Considering
90.239 and 37.064 annual PCI procedures with VCDs in Italy and Spain respectively
(1 VCD per procedure), 100% use of EXOSEAL™ vs. combined use of VCDs could save
2.680.870€ (95%-CI: 2.538.334€ – 2.823.405€) for the Italian NHS and 797.070€ (95%-CI:
734.231€ – 859.909€) for the Spanish NHS. CONCLUSIONS: This analysis suggests
use of EXOSEAL™ in patients undergoing PCI procedures may result in important
cost-savings for the Italian and the Spanish NHS. Additional data will be required to
confirm low complication rates with EXOSEAL™.
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OBJECTIVES: There has been growing interest in the potential benefits arising from
the use of medical diagnostic technologies, primarily due to possible reductions in
resource use and time to diagnosis. The objective of this study was to provide an
estimate of the potential financial implications resulting from the introduction of
Simtomax®, a rapid point of care test, for the diagnosis of coeliac disease and IgA
deficiency. The study, performed from the perspective of the UK NHS, aimed to
demonstrate that the additional test acquisition costs would be offset by resource
savings. METHODS: A 1 year budget impact model was developed looking at the
key financial drivers of diagnosing coeliac disease, based on the NICE pathway.
This included the cost of blood tests and other contributing costs, including GP
visits, nurse visits, paediatric outpatient visits for testing children and carriage.
The model compares Simtomax® to the current diagnosis pathway which com-
prises of serological testing for IgA tissue transglutaminase (tTGA) and a possible
IgA deficiency test, using ELISA laboratory testing. Costs were taken from national
sources with the exception of carriage costs which were estimated by a clinician as
a national source was not available. RESULTS: Although the cost of acquiring Sim-
tomax® was £22.51 greater than the cost of a tTGA test, an overall cost saving of
approximately £40.14 per patient was achieved as a result of resource savings. The
analysis estimated that the introduction of Simtomax® could result in cost savings
of up to £5,932,885 per annum to the UK NHS. CONCLUSIONS: The analysis sug-
gests that the use of Simtomax® for the diagnosis of coeliac disease would be
financially beneficial because it may result in decreased resource use and cost
savings. Additionally, the time required for health care professionals to diagnose
coeliac disease could be reduced meaning patients receive treatment faster.
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OBJECTIVES: The STERRAD® Sterilizers are a versatile group of systems that use
low-temperature, hydrogen peroxide gas plasma technology to sterilize medical
devices safely and effectively. Literature data suggest significant reductions in the
number of damaged rigid endoscopes with STERRAD® compared to steam steril-
ization. The aim of this study was to assess the potential savings associated with
the STERRAD®100NX™ system compared to steam for endoscope sterilization.
METHODS: A dynamic budget-impact model was developed to estimate the costs
with the use of the STERRAD® 100NX™ system compared to steam, from a hospital
decision-maker perspective and with a one-year time-horizon. Data were collected
from two Italian hospitals running approximately 800 sterilization cycles per year,
and costs of sterilization per cycle, endoscope repair costs, testing and mainte-
nance costs were considered. A conservative estimate for the endoscope repair
cost reduction of 33% was used in the base case analysis. Gamma distributions for
cost parameters and Bootstrap methods were used to generate 1000 simulations.
The acquisition costs of STERRAD® 100NX™ and steam systems were not
considered. RESULTS: In the base case analysis, the annual costs with STERRAD®
were €55,540, and the mean costs (SD) from the simulations were €51,471 (€25,186).
For steam sterilization, the corresponding figures were annual costs of €59,736 for
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